Orotic acid metabolite assemblies were evaluated in cultured SH-SY5Y cells using an XTT viability assay. At the highest tested concentration, cell viability decreased to about 50%. In C. trachomatis strain GO/86, serotype D, treatment with Orotic acid produced no significant reduction in infectivity, assessed by direct immunofluorescence counting of Chlamydia IFU. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell Viability Following Metabolite Assembly Exposure
Cell-based study · SH-SY5Y cell line [1]
Cultured SH-SY5Y cells were exposed to Orotic acid metabolite assemblies, and viability was assessed using an XTT assay. At the highest tested concentration, cell viability decreased to about 50%.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.2 mg/ml, 2 mg/ml, 1 mg/ml
- Exposure duration
- 6 hours at 37°C
- Method
- added to the cultured SH-SY5Y cell line
- Vehicle
- DMEM/Nutrient Mixture F12 (Ham’s) (1:1)
Methods and source locations
Compound reported in the paper: Orotic acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS (S23, S24, S25, S30); MATERIALS AND METHODS > Cell cytotoxicity experiments (S71, S75, S76); Fig. 3 legend (S115, S116, S121)
XTT cell viability assay: XTT cell viability assay; comparator: medium with no metabolites, which was treated in the same manner — RESULTS (S23, S25, S30); MATERIALS AND METHODS > Cell cytotoxicity experiments (S75); Fig. 3 legend (S115, S121)
Chlamydia infectivity following treatment
Cell-based study · C. trachomatis strain GO/86, serotype D [2]
C. trachomatis strain GO/86, serotype D, was treated with Orotic acid at 30 μM. No significant reduction in infectivity was observed by counting Chlamydia IFU using direct immunofluorescence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30 μM
- Exposure duration
- 7, 15 and 60 minutes
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Orotic acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Identification of Lactobacillus metabolic profiles associated with anti-Chlamydia activity (S71); Methods > C. trachomatis propagation and preparation of EBs (S88); Methods > C. trachomatis inhibition test (S98, S99, S102, S105)
counting Chlamydia IFU by direct immunofluorescence: counting Chlamydia IFU by direct immunofluorescence; comparator: The same amount of purified EBs was used as control — Results > Identification of Lactobacillus metabolic profiles associated with anti-Chlamydia activity (S71); Methods > C. trachomatis inhibition test (S105)